Regeneron (REGN) and Sanofi (SNY) Announce FDA Approval of DUPIXENT to Treat Moderate-to-Severe Atopic Dermatitis
Tweet Send to a Friend
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) today announced that the U.S. Food and Drug Administration (FDA) approved ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
